ELI LILLY AND COMPANY
NYSE: LLY (Eli Lilly and Company)
Last update: 3 hours ago1,347.11
-4.01 (-0.30%)
| Previous Close | 1,351.12 |
| Volume | 3,540,083 |
| Avg. Volume (3M) | 2,579,245 |
| Market Cap | 1,199,931,523,072 |
| Price / Earnings (TTM) | 43.85 |
| Price / Earnings (Forward) | 27.15 |
| Price / Sales | 14.32 |
| Price / Book | 30.60 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2026 |
| TTM Dividend Yield | 0.50% |
| Profit Margin | 31.90% |
| Operating Margin (TTM) | 51.25% |
| Diluted EPS (TTM) | 30.72 |
| Quarterly Revenue Growth (YOY) | 38.60% |
| Quarterly Earnings Growth (YOY) | 15.50% |
| Total Debt/Equity (MRQ) | 122.93% |
| Current Ratio (MRQ) | 1.39 |
| Operating Cash Flow (TTM) | 30.65 B |
| Levered Free Cash Flow (TTM) | 9.34 B |
| Return on Assets (TTM) | 21.06% |
| Return on Equity (TTM) | 86.02% |
News Mood
-
Positive Trial Results Could Be A Big Moment For Eli Lilly Stock
3 days ago, 1:11PM
-
Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
09 Nov, 8:30AM
-
A $4.7 Billion Fund Just Bought These 3 Stocks
16 hours ago
-
Eli Lilly (LLY) After ObesityWeek Is The Stock Still Undervalued
11 hours ago
-
Amgen (AMGN) Has Advanced MariTide Into Phase 3 Trials
yesterday, 8:19AM
-
What State Street Health Care SPDR (XLV) Sold: Eli Lilly Leads on Nov. 17
2 days ago, 5:05AM
AIStockmoo Score
| Value 30% | 0.5 |
| The price implies earnings growth of 21.6% a year; the business can fund about 15.0% a year. info | |
| Cheaper than its usual valuation. info | |
| Earns well above its cost of capital. Returns on capital rising. info | |
| High debt. Strong profitability. Positive cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | 2.8 |
| Uptrend over the past year. Trading near its 52-week high. info | |
| In an uptrend: the price is above its moving averages, and they are rising. It is close to them. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.2 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mixed or neutral. info | |
| Holdings' Sentiment info | NA |
| Smart Money 20% | -2.0 |
| Insiders net selling recently. info | |
| Institutions net -16.21% of shares in their latest 13F filings: 2,460 holders increased, 1,979 decreased (quarter to 30 Sep 2026). info | |
| Market and sector conditions are neutral. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Priced low for its earnings growth. info | |
| Earnings per share have gone up and down. info | |
| Above its medium-term trend line. info | |
| Price is high against its 52-week average. Up over 5 years. info | |
| Trend up on all three terms. Short-term momentum rising. info | |
| Price is near support. Levels trending down. info | |
| Final Score | 0.60 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Mixed | Bullish |
| Drug Manufacturers - General (Global) | Mixed | Bullish | |
| Stock | Eli Lilly and Company | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| LLY | 1 T | 0.50% | 43.85 | 30.60 | 0.6 |
| MRK | 327 B | 2.44% | 128.94 | 7.57 | -0.1 |
| NVS | 284 B | 3.09% | 28.72 | 7.87 | 1.7 |
| JNJ | 651 B | 1.98% | 41.04 | 8.05 | 0.4 |
| ABBV | 506 B | 2.44% | 49.18 | - | 0.3 |
| NVO | 171 B | 29.67% | 9.82 | 5.27 | 0.0 |
Select this tab to load the latest available analysis.
|
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Large Growth |
| % Held by Insiders | 0.19% |
| % Held by Institutions | 85.73% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lilly Endowment Inc | 30 Sep 2026 | 90,066,978 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| JONSSON PATRIK | - | 1,432.29 | -704 | -1,008,332 |
| Aggregate Net Quantity | -704 | |||
| Aggregate Net Value ($) | -1,008,332 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 1,432.29 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| JONSSON PATRIK | Officer | 10 Nov 2026 | Disposed (-) | 704 | 1,432.29 | 1,008,332 |
Institutions
Institutional ownership: 94.73%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 2,460 | 20,285,278 |
| Decreased | 1,979 | 150,872,918 |
| New | 225 | 5,994,988 |
| Sold out | 180 | 27,961,092 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
| Date | Type | Details |
|---|---|---|
| 20 Nov 2026 | Yahoo Finance |
Eli Lilly (LLY) After ObesityWeek Is The Stock Still Undervalued
Eli Lilly (LLY) is back in focus after ObesityWeek 2026, where the company released fresh clinical data on its obesity and sleep apnea pipeline, including EloraTZP, retatrutide and Foundayo. The latest ObesityWeek data arrived in a choppy tape for Eli Lilly. The share price has slipped about 2% in… |
| 20 Nov 2026 | Yahoo Finance |
What Does Eli Lilly Offer That Merck Does Not?
Today's big story: Will 2027 Be A 2022 Repeat For Stocks. |
| 20 Nov 2026 | Yahoo Finance |
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?
Eli Lilly's revenue is climbing at a pace AbbVie can't match, yet AbbVie trades at a noticeably lower earnings multiple. |
| 20 Nov 2026 | Yahoo Finance |
A $4.7 Billion Fund Just Bought These 3 Stocks
Key TakeawaysKinetic Partners Management, a firm that manages $4. 73 billion, made its three biggest third-quarter additions in Eli Lilly, Microsoft and CoreWeave, its 13F filed Nov. |
| 20 Nov 2026 | Yahoo Finance |
Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?
Lilly and Pfizer offer contrasting growth stories driven by blockbuster drugs, expanding pipelines and strategic investments. |
| 20 Nov 2026 | Yahoo Finance |
iShares U.S. Healthcare ETF (IYH) Sells $17.4 Million of Eli Lilly on Wednesday
The fund sold $105.9 million of stock and bought nothing, cutting all 99 of its positions. |
| 20 Nov 2026 | Yahoo Finance |
What State Street Health Care SPDR (XLV) Sold: Eli Lilly Leads on Wednesday
The fund sold $335.2 million of stock on Wednesday, Nov. 18, cutting all 60 of its positions and buying nothing. |
| 20 Nov 2026 | Yahoo Finance |
ETFs Are Net Sellers of Eli Lilly (LLY) on Nov. 18
ETFs sold $252.2 million of Eli Lilly (LLY) on Wednesday, with 39 buying and 20 selling. |
| 19 Nov 2026 | Yahoo Finance |
Jefferies Has Wall Street’s Highest Target on Eli Lilly (LLY). Why?
We just published a list of the Morgan Stanley’s Vintage Values 2027: 10 Stocks Analysts See Climbing Further and Eli Lilly (NYSE:LLY) ranked 10th on this list. Bloomberg reported on November 13, 2026, that one bank’s strategists expect the S&P 500 to reach 8,700 within 12 months. They also see… |
| 19 Nov 2026 | Yahoo Finance |
Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance
Sanofi and Regeneron both scored in the rare disease space while Lilly's dealmaking streak continued. |
| 19 Nov 2026 | Yahoo Finance |
Eli Lilly (LLY) – The Only Healthcare Name in Ken Fisher’s Fastest-Growing Top Positions
Eli Lilly and Company (NYSE:LLY) rounds out our list of the Top 10 Stocks to Buy According to Billionaire Ken Fisher at number 10. Ken Fisher has spent more than four decades betting that big, globally dominant companies keep winning, and his latest filing shows he still believes it. Fisher Asset… |
| 19 Nov 2026 | Yahoo Finance |
$1,000 Invested in Eli Lilly 10 Years Ago Would Be Worth a Fortune Today
One molecule turned a diversified drugmaker into a trillion-dollar giant, yet recent buyers have watched shares swing hard even as revenue surged. Does Lilly's next chapter justify today's price, or has the best part already happened? |
| 19 Nov 2026 | Yahoo Finance |
General Medicine Brings its GLP-1 Weight Management Care to LillyDirect
General Medicine, a healthcare store founded by the team behind PillPack and Amazon Pharmacy, today announced that its GLP-1 weight management care is available to customers through LillyDirect, Eli Lilly and Company's digital direct to consumer healthcare platform, as one of the independent care… |
| 19 Nov 2026 | Yahoo Finance |
Sector Rotation Dragged Eli Lilly (LLY) Down in Q3 Despite Intact Momentum
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q3 2026 investor letter. The letter can be downloaded here. U.S. equity markets rose modestly in the third quarter, with the S&P 500 gaining 2.30% and the… |
| 19 Nov 2026 | Yahoo Finance |
Eli Lilly Stopped Touting Dose Counts. Should You Worry?
Today's big story: Could Anthropic Stock Fall 25… |
| 19 Nov 2026 | Yahoo Finance |
Amgen (AMGN) Has Advanced MariTide Into Phase 3 Trials
Amgen (NasdaqGS:AMGN) has advanced its obesity drug candidate MariTide into Phase 3 clinical trials, targeting the growing anti-obesity treatment market. The firm is positioning MariTide to compete with existing anti-obesity therapies from established players such as Eli Lilly and Novo Nordisk.… |
| 19 Nov 2026 | Yahoo Finance |
Is Immunology Emerging as Eli Lilly's Next Growth Driver?
Lilly is expanding its immunology franchise through growing drug sales, promising pipeline candidates and strategic acquisitions. |
| 19 Nov 2026 | Yahoo Finance |
Eli Lilly (LLY) Expands Its Oncology Research Platform
Eli Lilly (NYSE: LLY) has agreed to acquire Calytrix Bio to add rare blood cancer programs to its oncology pipeline. The firm also announced a multi-target oncology collaboration with Stipple Bio focused on precision cancer therapies for solid tumors. Together, the Calytrix Bio acquisition and… |
| 19 Nov 2026 | Yahoo Finance |
What State Street Health Care SPDR (XLV) Sold: Eli Lilly Leads on Nov. 17
The fund cut all 60 of its positions, selling $250.1 million of stock, led by Eli Lilly at $42.3 million. |
| 18 Nov 2026 | Yahoo Finance |
Lilly Buying Spree Surpasses $32B
Bloomberg's Madison Muller joins Dani Burger on "Bloomberg Deals." Eli Lilly agreed to buy closely held Calytrix Bio in a deal that could be worth up to $1.5 billion, the latest in the drugmaker's $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. |
| 18 Nov 2026 | Yahoo Finance |
Health Canada approves Lilly's Mounjaro® (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
Eli Lilly Canada today announced that Health Canada has issued a Notice of Compliance (NOC) for Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal… |
| 18 Nov 2026 | Yahoo Finance |
Is Lilly Stock's Winning Streak Skill Or Luck?
Today's big story: Anthropic IPO: Priced For 2031, Or 2036… |
| 18 Nov 2026 | Yahoo Finance |
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts. |
| 18 Nov 2026 | Yahoo Finance |
48 ETFs Add to Lilly (LLY) Holdings on Nov. 16
ETFs bought $141.8 million of Eli Lilly (LLY) shares on Monday. |
| 17 Nov 2026 | Yahoo Finance |
Eli Lilly Is Up 39% in a Year. Barclays Sees Another 9%
Key TakeawaysBarclays raised its Eli Lilly price target to $1,550 from $1,400 and kept its Overweight rating, with the stock close to a 52-week high. Lilly’s third-quarter revenue rose 39% to $24… |
| 17 Nov 2026 | Yahoo Finance |
Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
Lilly's revenue growth is turbocharged by its weight-loss pipeline, while Novo's global footprint and far lower valuation raise a tougher question about risk versus reward. |
| 17 Nov 2026 | Yahoo Finance |
Third-Party Vendor Linked to Eli Lilly Is Hit by Data Breach
Lilly found no unauthorized access to its own systems, a person familiar with the matter said. Extortion group n0n claims to hold patient and prescriber data. |
| 17 Nov 2026 | Yahoo Finance |
Positive Trial Results Could Be A Big Moment For Eli Lilly Stock
Eli Lilly used ObesityWeek 2026 to share late-stage data on EloraTZP, retatrutide and Foundayo, showing strong effects on weight, A1C, sleep apnea severity and knee osteoarthritis pain in adults with obesity and related conditions. The breadth of positive findings across multiple organs and… |
| 17 Nov 2026 | Yahoo Finance |
Eli Lilly inks cancer pact worth up to $5.9bn with Stipple Bio
Stipple plans to initiate a Phase I trial for an ADC for solid tumours in early 2027… |
| 17 Nov 2026 | Yahoo Finance |
Cathie Wood and 9 Other Big Funds Bought Eli Lilly Last Quarter, While 18 Sold. Who’s Right?
Key TakeawaysOf 456 big funds that have filed 13Fs for the quarter ended Sept. 30, 10 bought Eli Lilly and 18 sold. |
| 17 Nov 2026 | Yahoo Finance |
A $1.5 Billion Reason Why Eli Lilly Stock Is in Focus
Eli Lilly announces $1.5 billion deal to acquire Calytrix Bio. Here’s what the transaction really means for LLY shares. |
| 17 Nov 2026 | Yahoo Finance |
Lilly agrees to acquire Calytrix Bio for $1.5bn
Calytrix Bio shareholders could receive an upfront payment followed by payouts contingent on reaching clinical and regulatory milestones. |
| 17 Nov 2026 | Yahoo Finance |
Was Eli Lilly Stock's 45% Run Visible Early?
Today's big story: Could Nvidia Stock Fall 50%? Follow The Cash. |
| 16 Nov 2026 | Yahoo Finance |
Lilly Bets Up to $1.5 Billion on Calytrix's Preclinical Antibody
The deal is Lilly's second blood cancer acquisition this year, after Ajax Therapeutics… |
| 16 Nov 2026 | Yahoo Finance |
Eli Lilly Makes $1.5 Billion Move Beyond Weight-Loss Drugs
Calytrix is developing an early-stage antibody treatment for essential thrombocythemia and myelofibrosis. |
| 16 Nov 2026 | Yahoo Finance |
Eli Lilly is trouncing Nvidia — and the weight-loss drug trade is beating AI again
Since its Oct. 6 record, Nvidia has shed more than $1.7 trillion in market value. Eli Lilly has added more than $250 billion over the same stretch, a gain topped only by Apple among the market's biggest stocks. |
| 16 Nov 2026 | Yahoo Finance |
CVS Sees a Possible Break-Even Point for GLP-1s
Drugmakers could gain patients while earning less per prescription. |
| 16 Nov 2026 | Yahoo Finance |
CVS white paper aims to pressure drugmakers to lower GLP-1 prices
GLP-1s would save employers money in the long term if priced at $350 a month or less, the company found. “I would love to see this pressure [drugmakers] to bring down prices to something rational,” CMO Amy Compton-Phillips said. |
| 16 Nov 2026 | Yahoo Finance |
Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035
Lilly's Mounjaro and Zepbound Earn USD 16.1 Billion in One Quarter, Novo's Obesity Sales Rise 22% and Oral GLP-1 Pills Open a New Front: Precedence Research Company Intelligence on Leaders, Pipelines, Investments and DealsOttawa, Nov. 16, 2026 (GLOBE NEWSWIRE) -- The global anti-obesity drugs… |
| 16 Nov 2026 | Yahoo Finance |
Eli Lilly to acquire Calytrix Bio in deal worth up to $1.5 billion
Eli Lilly and Co (NYSE:LLY) has agreed to acquire privately held biotechnology company Calytrix Bio for up to $1.5 billion in cash, expanding its efforts to develop treatments for rare blood disorders and strengthen its presence in haematology. Under the definitive agreement, Calytrix… |
| 16 Nov 2026 | Yahoo Finance |
Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion to Expand Blood Cancer Portfolio
Eli Lilly and Company (NYSE:LLY) has agreed to acquire privately held biotechnology company Calytrix Bio in a cash transaction valued at up to $1. 5 billion, expanding its development portfolio of treatments for rare blood cancers. |
| 16 Nov 2026 | Yahoo Finance |
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
| 16 Nov 2026 | Yahoo Finance |
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
Lilly’s 15th announced company acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms. |
| 16 Nov 2026 | Yahoo Finance |
What Does Eli Lilly (LLY) Reveal At ObesityWeek 2026 About Its Growth Path?
Eli Lilly (NYSE:LLY) released new clinical data at ObesityWeek 2026 on Zepbound, Foundayo, EloraTZP, and retatrutide. The update included late-stage obesity and cardiometabolic results that covered weight loss, metabolic markers, and related chronic conditions. Data presented highlighted efficacy… |
| 16 Nov 2026 | Yahoo Finance |
State Street Health Care SPDR (XLV) Sells Eli Lilly and J&J on Nov. 12
The fund sold $300.3 million of stock, cutting all 60 positions and adding nothing, as its assets stood at $50.56 billion. |
| 16 Nov 2026 | Yahoo Finance |
ETFs Are Net Sellers of Eli Lilly (LLY) on Nov. 12
Eli Lilly (LLY) drew $300.9 million in net ETF selling Thursday. |
| 16 Nov 2026 | Yahoo Finance |
Big-name investors pour $100M into DNA therapeutics developer Seawolf
The startup, which also just disclosed an up to $1.2 billion partnership with Sanofi, is backed by Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm. |
| 09 Nov 2026 | CNBC |
Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity. |
| 02 Oct 2026 | CNBC | Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s |
| 30 Sep 2026 | CNBC | Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial |
| 30 Sep 2026 | CNBC | People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study |
| 25 Sep 2026 | CNBC | Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s |
| 21 Sep 2026 | CNBC | Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs |
| 21 Sep 2026 | CNBC | Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production |
| 14 Sep 2026 | CNBC | Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy |
| 31 Aug 2026 | CNBC | Trump strikes new drug pricing deals with nine midsized drugmakers |
| Show more | ||
| TTM Dividend Yield | 0.50% |
| 5Y Average Dividend Yield | 0.78% |
| Payout Ratio | 21.71% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 14 Feb 2025 | 09 Dec 2024 | 10 Mar 2025 | 1.5 Cash |
| 15 Nov 2024 | 28 Oct 2024 | 10 Dec 2024 | 1.3 Cash |
| 15 Aug 2024 | 24 Jun 2024 | 10 Sep 2024 | 1.3 Cash |
| 15 May 2024 | 06 May 2024 | 10 Jun 2024 | 1.3 Cash |
| 14 Feb 2024 | 08 Dec 2023 | 08 Mar 2024 | 1.3 Cash |
| 14 Nov 2023 | 01 Nov 2023 | 08 Dec 2023 | 1.13 Cash |
| 14 Aug 2023 | 26 Jun 2023 | 08 Sep 2023 | 1.13 Cash |
| 12 May 2023 | 01 May 2023 | 09 Jun 2023 | 1.13 Cash |
| 14 Feb 2023 | 12 Dec 2022 | 10 Mar 2023 | 1.13 Cash |
| 14 Nov 2022 | 17 Oct 2022 | 09 Dec 2022 | 0.98 Cash |
| 12 Aug 2022 | 27 Jun 2022 | 09 Sep 2022 | 0.98 Cash |
| 13 May 2022 | 02 May 2022 | 10 Jun 2022 | 0.98 Cash |
| 14 Feb 2022 | 13 Dec 2021 | 10 Mar 2022 | 0.98 Cash |
| 12 Nov 2021 | 18 Oct 2021 | 10 Dec 2021 | 0.85 Cash |
| 12 Aug 2021 | 29 Jun 2021 | 10 Sep 2021 | 0.85 Cash |
| 13 May 2021 | 03 May 2021 | 10 Jun 2021 | 0.85 Cash |
| 11 Feb 2021 | 14 Dec 2020 | 10 Mar 2021 | 0.85 Cash |
| 12 Nov 2020 | 19 Oct 2020 | 10 Dec 2020 | 0.74 Cash |
| 13 Aug 2020 | 15 Jul 2020 | 10 Sep 2020 | 0.74 Cash |
| 14 May 2020 | 04 May 2020 | 10 Jun 2020 | 0.74 Cash |
| 13 Feb 2020 | 16 Dec 2019 | 10 Mar 2020 | 0.74 Cash |
| 14 Nov 2019 | 22 Oct 2019 | 10 Dec 2019 | 0.645 Cash |
| 14 Aug 2019 | 20 Jun 2019 | 10 Sep 2019 | 0.645 Cash |
| 16 May 2019 | 07 May 2019 | 10 Jun 2019 | 0.645 Cash |
| 14 Feb 2019 | 19 Dec 2018 | 08 Mar 2019 | 0.645 Cash |
| 14 Nov 2018 | 16 Oct 2018 | 10 Dec 2018 | 0.5625 Cash |
| 14 Aug 2018 | 19 Jun 2018 | 10 Sep 2018 | 0.5625 Cash |
| 16 May 2018 | 07 May 2018 | 08 Jun 2018 | 0.5625 Cash |
| 14 Feb 2018 | 11 Dec 2017 | 09 Mar 2018 | 0.5625 Cash |
| 14 Nov 2017 | 16 Oct 2017 | 08 Dec 2017 | 0.52 Cash |
| 11 Aug 2017 | 19 Jun 2017 | 08 Sep 2017 | 0.52 Cash |
| 11 May 2017 | 01 May 2017 | 09 Jun 2017 | 0.52 Cash |
| 13 Feb 2017 | 12 Dec 2016 | 10 Mar 2017 | 0.52 Cash |
| 10 Nov 2016 | 17 Oct 2016 | 09 Dec 2016 | 0.51 Cash |
| 11 Aug 2016 | 20 Jun 2016 | 09 Sep 2016 | 0.51 Cash |
| 11 May 2016 | 02 May 2016 | 10 Jun 2016 | 0.51 Cash |
| 10 Feb 2016 | 08 Dec 2015 | 10 Mar 2016 | 0.51 Cash |
| 10 Nov 2015 | 19 Oct 2015 | 10 Dec 2015 | 0.5 Cash |
| 12 Aug 2015 | 15 Jun 2015 | 10 Sep 2015 | 0.5 Cash |
| 14 May 2015 | 04 May 2015 | 10 Jun 2015 | 0.5 Cash |
| 11 Feb 2015 | 15 Dec 2014 | 10 Mar 2015 | 0.5 Cash |
| 12 Nov 2014 | 20 Oct 2014 | 10 Dec 2014 | 0.49 Cash |
| 13 Aug 2014 | 16 Jun 2014 | 10 Sep 2014 | 0.49 Cash |
| 13 May 2014 | 05 May 2014 | 10 Jun 2014 | 0.49 Cash |
| 12 Feb 2014 | 16 Dec 2013 | 10 Mar 2014 | 0.49 Cash |
| 13 Nov 2013 | 21 Oct 2013 | 10 Dec 2013 | 0.49 Cash |
| 13 Aug 2013 | 18 Jun 2013 | 10 Sep 2013 | 0.49 Cash |
| 14 May 2013 | 03 May 2013 | 10 Jun 2013 | 0.49 Cash |
| 13 Feb 2013 | 17 Dec 2012 | 08 Mar 2013 | 0.49 Cash |
| 13 Nov 2012 | 15 Oct 2012 | 10 Dec 2012 | 0.49 Cash |
| 13 Aug 2012 | 19 Jun 2012 | 10 Sep 2012 | 0.49 Cash |
| 13 Feb 2012 | 12 Dec 2011 | 09 Mar 2012 | 0.49 Cash |
| 10 Nov 2011 | 17 Oct 2011 | 09 Dec 2011 | 0.49 Cash |
| 11 Aug 2011 | 20 Jun 2011 | 09 Sep 2011 | 0.49 Cash |
| 11 May 2011 | 18 Apr 2011 | 10 Jun 2011 | 0.49 Cash |
| 11 Feb 2011 | 13 Dec 2010 | 10 Mar 2011 | 0.49 Cash |
| 10 Nov 2010 | 18 Oct 2010 | 10 Dec 2010 | 0.49 Cash |
| 11 Aug 2010 | 21 Jun 2010 | 10 Sep 2010 | 0.49 Cash |
| 12 May 2010 | 19 Apr 2010 | 10 Jun 2010 | 0.49 Cash |
| 10 Feb 2010 | 14 Dec 2009 | 10 Mar 2010 | 0.49 Cash |
| 10 Nov 2009 | 19 Oct 2009 | 10 Dec 2009 | 0.49 Cash |
| 12 Aug 2009 | 22 Jun 2009 | 10 Sep 2009 | 0.49 Cash |
| 13 May 2009 | 20 Apr 2009 | 10 Jun 2009 | 0.49 Cash |
| 11 Feb 2009 | 15 Dec 2008 | 10 Mar 2009 | 0.49 Cash |
| 12 Nov 2008 | 20 Oct 2008 | 10 Dec 2008 | 0.47 Cash |
| 13 Aug 2008 | 20 Jun 2008 | 10 Sep 2008 | 0.47 Cash |
| 13 Feb 2008 | 17 Dec 2007 | 10 Mar 2008 | 0.47 Cash |
| 13 Nov 2007 | 15 Oct 2007 | 10 Dec 2007 | 0.425 Cash |
| 13 Aug 2007 | 21 Jun 2007 | 10 Sep 2007 | 0.425 Cash |
| 11 May 2007 | 16 Apr 2007 | 08 Jun 2007 | 0.425 Cash |
| 13 Feb 2007 | 18 Dec 2006 | 09 Mar 2007 | 0.425 Cash |
| 13 Nov 2006 | 16 Oct 2006 | 08 Dec 2006 | 0.4 Cash |
| 11 Aug 2006 | 26 Jun 2006 | 08 Sep 2006 | 0.4 Cash |
| 11 May 2006 | 24 Apr 2006 | 09 Jun 2006 | 0.4 Cash |
| 13 Feb 2006 | 19 Dec 2005 | 10 Mar 2006 | 0.4 Cash |
| 10 Nov 2005 | 17 Oct 2005 | 09 Dec 2005 | 0.38 Cash |
| 11 Aug 2005 | 24 Jun 2005 | 09 Sep 2005 | 0.38 Cash |
| 11 May 2005 | 18 Apr 2005 | 10 Jun 2005 | 0.38 Cash |
| 11 Feb 2005 | 20 Dec 2004 | 10 Mar 2005 | 0.38 Cash |
| 10 Nov 2004 | 18 Oct 2004 | 10 Dec 2004 | 0.355 Cash |
| 11 Aug 2004 | 28 Jun 2004 | 10 Sep 2004 | 0.355 Cash |
| 12 May 2004 | 19 Apr 2004 | 10 Jun 2004 | 0.355 Cash |
| 11 Feb 2004 | 15 Dec 2003 | 10 Mar 2004 | 0.355 Cash |
| 12 Nov 2003 | 20 Oct 2003 | 10 Dec 2003 | 0.335 Cash |
| 13 Aug 2003 | 23 Jun 2003 | 10 Sep 2003 | 0.335 Cash |
| 13 May 2003 | 28 Apr 2003 | 10 Jun 2003 | 0.335 Cash |
| 12 Feb 2003 | 16 Dec 2002 | 10 Mar 2003 | 0.335 Cash |
| 13 Nov 2002 | 21 Oct 2002 | 10 Dec 2002 | 0.31 Cash |
| 13 Aug 2002 | 24 Jun 2002 | 10 Sep 2002 | 0.31 Cash |
| 13 May 2002 | 15 Apr 2002 | 10 Jun 2002 | 0.31 Cash |
| 13 Feb 2002 | 17 Dec 2001 | 08 Mar 2002 | 0.31 Cash |
| 13 Nov 2001 | 15 Oct 2001 | 10 Dec 2001 | 0.28 Cash |
| 13 Aug 2001 | 25 Jun 2001 | 10 Sep 2001 | 0.28 Cash |
| 11 May 2001 | 16 Apr 2001 | 11 Jun 2001 | 0.28 Cash |
| 13 Feb 2001 | 18 Dec 2000 | 09 Mar 2001 | 0.28 Cash |
| 13 Nov 2000 | 16 Oct 2000 | 11 Dec 2000 | 0.26 Cash |
| 11 Aug 2000 | 26 Jun 2000 | 11 Sep 2000 | 0.26 Cash |
| 11 May 2000 | 17 Apr 2000 | 09 Jun 2000 | 0.26 Cash |
| 11 Feb 2000 | 20 Dec 1999 | 10 Mar 2000 | 0.26 Cash |
| 10 Nov 1999 | 18 Oct 1999 | 10 Dec 1999 | 0.23 Cash |
| 11 Aug 1999 | 19 Jul 1999 | 10 Sep 1999 | 0.23 Cash |
| 12 May 1999 | 19 Apr 1999 | 10 Jun 1999 | 0.23 Cash |
| 10 Feb 1999 | 21 Dec 1998 | 10 Mar 1999 | 0.23 Cash |
| 10 Nov 1998 | 20 Oct 1998 | 10 Dec 1998 | 0.2 Cash |
| 12 Aug 1998 | 20 Jul 1998 | 10 Sep 1998 | 0.2 Cash |
| 13 May 1998 | 20 Apr 1998 | 10 Jun 1998 | 0.2 Cash |
| 11 Feb 1998 | 15 Dec 1997 | 10 Mar 1998 | 0.2 Cash |
| 12 Nov 1997 | 15 Sep 1997 | 10 Dec 1997 | 0.2 Cash |
| 13 Aug 1997 | 21 Jul 1997 | 10 Sep 1997 | 0.36 Cash |
| 13 May 1997 | 21 Apr 1997 | 10 Jun 1997 | 0.36 Cash |
| 12 Feb 1997 | 16 Dec 1996 | 10 Mar 1997 | 0.36 Cash |
| 13 Nov 1996 | 21 Oct 1996 | 10 Dec 1996 | 0.3425 Cash |
| 13 Aug 1996 | 15 Jul 1996 | 10 Sep 1996 | 0.3425 Cash |
| 13 May 1996 | 15 Apr 1996 | 10 Jun 1996 | 0.3425 Cash |
| 13 Feb 1996 | 18 Dec 1995 | 11 Mar 1996 | 0.3425 Cash |
| 13 Nov 1995 | 17 Oct 1995 | 11 Dec 1995 | 0.685 Cash |
| 11 Aug 1995 | 17 Jul 1995 | 11 Sep 1995 | 0.645 Cash |
| 09 May 1995 | 17 Apr 1995 | 12 Jun 1995 | 0.645 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 1.50 | 1 | 0.14 |
| 2024 | 5.20 | 4 | 0.67 |
| 2023 | 4.52 | 4 | 0.78 |
| 2022 | 3.92 | 4 | 1.07 |
| 2021 | 3.40 | 4 | 1.23 |
| 2020 | 2.96 | 4 | 1.75 |
| 2019 | 2.58 | 4 | 1.96 |
| 2018 | 2.25 | 4 | 1.94 |
| 2017 | 2.08 | 4 | 2.46 |
| 2016 | 2.04 | 4 | 2.77 |
| 2015 | 2.00 | 4 | 2.37 |
| 2014 | 1.96 | 4 | 2.84 |
| 2013 | 1.96 | 4 | 3.84 |
| 2012 | 1.47 | 3 | 2.98 |
| 2011 | 1.96 | 4 | 4.72 |
| 2010 | 1.96 | 4 | 5.59 |
| 2009 | 1.96 | 4 | 5.49 |
| 2008 | 1.41 | 3 | 3.50 |
| 2007 | 1.70 | 4 | 3.18 |
| 2006 | 1.60 | 4 | 3.07 |
| 2005 | 1.52 | 4 | 2.69 |
| 2004 | 1.42 | 4 | 2.50 |
| 2003 | 1.34 | 4 | 1.91 |
| 2002 | 1.24 | 4 | 1.95 |
| 2001 | 1.12 | 4 | 1.43 |
| 2000 | 1.04 | 4 | 1.12 |
| 1999 | 0.920 | 4 | 1.38 |
| 1998 | 0.800 | 4 | 0.90 |
| 1997 | 1.28 | 4 | 1.84 |
| 1996 | 1.37 | 4 | 3.75 |
| 1995 | 1.98 | 3 | 7.02 |
| Show more | |||
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |